Multicenter randomized phase II study of docetaxel (Doc) given q3w vs q1w plus trastuzumab (Tra) as first line therapy for HER2 overexpressing adjuvant anthracyclin pretreated metastatic breast cancer (MBC).

G Raab, W Brugger, N Harbeck, E Heidemann,G Schaller,D Wallwiener, L Bacchus,H Eidtmann, K Friese, R Goebel,J Hilfrich,K Hoeffken, R Kreienberg, R Kuhn, W Loehr,U Nitz,H Wolf, T Buechele, E Eiermann,M De Wit

BREAST CANCER RESEARCH AND TREATMENT（2002）

Cited 0|Views22

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined